Key takeaways
- Enteric-coated peppermint oil has a short-term IBS symptom signal in pooled trials, but the 2022 review rated certainty very low and newer trials have not consistently confirmed it
- A fully verified independent-only effect estimate is unavailable; these findings do not establish a dependable benefit for every retail product
- Peppermint oil, peppermint tea, isolated menthol and peppermint–caraway combinations have different evidence
- Reflux and heartburn can worsen. An enteric coating reduces early release; it does not guarantee freedom from side effects
- A large 2026 pediatric trial found no advantage over its comparator. Adult results should not be turned into a children's self-treatment recommendation
Peppermint oil has mixed short-term IBS results. The 2022 adult synthesis reported pooled symptom relief with very low certainty; its low-bias global-symptom subgroup was inconclusive, while its pain subgroup remained positive with wide uncertainty. Modern adult trials missed primary endpoints, and a 2026 pediatric trial found no superiority. Known commercial ties and unreported supply terms prevent a fully verified independent-only estimate. Reflux can worsen; the reviewed human studies do not establish gut-healing or antimicrobial treatment. Adult review, US trial, Dutch trial, Pediatric trial, Safety guidance
Contents
Evidence summary · What it is · Selected formulations · Mechanism · Hype · Benefits · Verdicts · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources
Evidence summary
Favorable trial results and financial independence are separate questions. Commercially supported trials are retained as clinical context, including null findings. Some full reports or procurement terms remain unavailable, so this review cannot calculate a fully verified independent-only pooled benefit. Missing information remains unknown. Review, US trial, PERSUADE, Pediatric trial
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Relieves adult IBS symptoms | Pooled benefit, with very low certainty and more adverse events | Ingrosso 2022, accepted manuscript | Accepted main paper recovered; no separate review financial declaration found in that version; mixed underlying provenance | Possible benefit; insufficient independent estimate |
| Improves IBS compared with placebo in a modern US trial | No significant primary or secondary advantage | Nee 2021 | NIH funding verified; full final disclosure and procurement terms unresolved | Important null trial; not proof of universal inefficacy |
| Improves modern IBS responder endpoints | Both tested release formulations missed primary endpoints; some small-intestinal-release secondary results favored oil | Weerts 2020 | Public grant plus explicit in-kind capsules, commercial collaboration and licensing interests | Known commercial ties; not independent-only corroboration |
| Helps children with IBS or functional abdominal pain | No superiority in a 228-child trial | Vermeijden 2026 | Charity support; manufacturer provision with payment terms unknown; indirect author ties | Does not establish pediatric benefit |
| Treats functional dyspepsia by itself | Combination research cannot isolate peppermint oil | Chey 2019 | IM HealthScience funding and author ties | Insufficient for oil alone |
| Raises some medicine exposure | Small human felodipine experiment; cyclosporine finding is from rats | Dresser 2002; Wacher 2002 | AvMax affiliations; complete financing unresolved | Limited interaction signal, not a universal drug-interaction rule |
What it is
Peppermint, Mentha × piperita, is a hybrid of water mint and spearmint. Its essential oil is a concentrated preparation obtained from the plant's aerial material, including leaves and flowering parts. Menthol is an important constituent, but the oil contains multiple compounds. Leaf tea, an oil capsule and isolated menthol are not dose-equivalent preparations. NCCIH ingredient overview
This article concerns swallowed preparations and digestive claims. Aromatherapy for nausea, topical treatment, dental products and clinician-administered endoscopic preparations require separate evidence. A procedural antispasmodic effect cannot establish that a retail capsule improves a chronic digestive disorder.
Selected formulations
| Form | Important distinction | What to check |
|---|---|---|
| Gastro-resistant or enteric-coated capsules | Coating delays exposure until after the stomach | Exact release system, amount per capsule and instructions |
| Small-intestinal-release microspheres | A proprietary delivery system can differ from a conventional capsule | Evidence for that complete formulation |
| Ileocolonic-release capsules | Intended delivery farther down the bowel | This formulation did not outperform placebo on the main endpoints in Weerts' trial |
| Uncoated oil or essential-oil drops | Concentrated oil can contact the mouth, oesophagus and stomach directly | Do not improvise an oral dose from an aromatherapy bottle |
| Peppermint tea or leaf extract | Different composition and exposure | Capsule findings do not establish equivalent effectiveness |
| Isolated menthol or peppermint plus caraway | Another molecule or a combination intervention | Attribute findings to the studied intervention |
Release location is part of the treatment, not a cosmetic feature. “Natural,” “ultrapurified” or “clinical strength” does not show independent clinical superiority. The examined products include a UK-authorized 0.2 mL capsule and proprietary US supplements; regulatory status and excipients differ. Colpermin product information, IBgard manufacturer page
How it works
The central rationale is relaxation of gastrointestinal smooth muscle. Laboratory pharmacology implicates calcium-dependent contraction, while menthol-sensitive sensory pathways are also being investigated. Enteric coatings aim to deliver the oil farther down the digestive tract. These mechanisms make an antispasmodic effect plausible; they do not tell us the size or durability of pain relief in everyday IBS. NHS mechanism explanation, regulated product pharmacology
IBS symptoms fluctuate, and participants can improve with reassurance, follow-up, background treatment or placebo. Consequently, a before-and-after improvement is less informative than the difference from a well-matched control. The NIH-supported peppermint study was nested within a placebo-research program, making that distinction particularly relevant. Ballou protocol
Hype versus evidence
The reasonable claim is limited symptom relief in a defined setting. Claims that peppermint repairs the intestinal barrier, eliminates SIBO, restores a microbiome, treats inflammatory bowel disease or cures every kind of bloating go beyond the human outcomes reviewed here. Laboratory antimicrobial activity would not establish eradication of a diagnosed infection, and pain relief would not demonstrate mucosal healing.
The American College of Gastroenterology's 2021 guideline conditionally suggested peppermint for global IBS symptoms using low-quality evidence. That is a treatment option within clinical care, not a guarantee of benefit or a finding that all underlying studies were commercially independent. ACG guideline
A manufacturer currently promotes targeted delivery and rapid abdominal comfort. Those statements identify what is being marketed; they do not supply independent corroboration. Manufacturer's claim
Benefits by claim
Adult IBS pain and global symptoms Insufficient independent evidence
The 2022 synthesis included 10 adult randomized trials and 1,030 participants. Failure-to-improve relative risks were 0.65 (95% CI 0.43–0.98) for global symptoms and 0.76 (0.62–0.93) for pain. The global-symptom NNT was 4 with a wide 2.5–71 interval. Among low-risk-of-bias studies, global improvement was inconclusive (two trials, 261 participants; RR 0.77, 0.28–2.08), while pain remained positive but imprecise (three trials, 351 participants; RR 0.78, 0.61–0.99). Heterogeneity, publication-bias concerns and imputed pain-response counts limit the estimates; the authors rated certainty very low. Commercially linked trials are included, so this is not an independent-only effect estimate. Ingrosso 2022, accepted original manuscript
Nee’s US trial tested 180 mg three times daily for six weeks. Mean symptom-severity improvement was 90.8 points with peppermint and 100.3 with placebo, with no significant between-group difference; reported secondary comparisons were also null. NIH financing is documented. The related prospective protocol describes 0.2 mL Pepogest softgels and a manufactured soybean-oil placebo, without purchase or donation terms. The completed paper’s full methods and financial declarations remain unrecovered. Public grant support therefore does not fully resolve provenance or establish universal ineffectiveness. Nee 2021, prospective protocol, NIH award
The Dutch PERSUADE trial found no significant advantage on either prespecified pain-responder or overall-relief endpoint after eight weeks. Some exploratory small-intestinal-release pain, discomfort and severity comparisons favored oil; this was not consistent across measures or visits, and the trial used stricter multiplicity thresholds. Six-month follow-up after stopping treatment did not show significant group differences. Will Pharma supplied capsules in kind, collaborated on the study and held relevant commercial agreements; author and employer licensing relationships were disclosed. Public grant support does not remove those ties. Weerts 2020, published original with tables and disclosures
Cash’s four-week trial involved 72 adults with diarrhea-predominant or mixed IBS and a targeted-delivery preparation. Its primary symptom-score improvement was 40% with oil versus 24.3% with placebo (p = 0.0246). The short study used restricted background/rescue treatments and last-observation carry-forward; it does not establish every IBS subtype or long-term benefit. IM HealthScience funded it, and the authors included a company consultant and medical/innovation officers. These are formulation-specific findings with direct commercial ties. Cash 2016
Children's IBS and functional abdominal pain Insufficient
In the 2026 multicenter Dutch trial, 228 children aged 8–18 were randomized to peppermint-oil capsules, peppermint sweets or comparator capsules. Treatment success was 44.0% with oil and 37.3% with comparator, a nonsignificant difference; sweets also showed no advantage. Adequate relief did not differ significantly. The comparator contained a small amount of peppermint oil for blinding, so it was not chemically oil-free. The funding statement names SPIN/Cultuurfonds support and products provided by Will Pharma and Fortuin; payment terms are not specified. Keszthelyi disclosed earlier Will Pharma co-funding, and Benninga disclosed several company consultancies. These findings do not justify routine pediatric self-treatment. Vermeijden 2026
Functional dyspepsia and upper abdominal discomfort Insufficient for oil alone
The 2019 FDREST trial tested duodenal-release caraway oil plus L-menthol, rather than peppermint oil alone. In 95 analyzed adults, a 24-hour postprandial-distress comparison favored the combination, but overall global improvement at two and four weeks and the four-week clinical global comparison were not significant. Selected subgroup findings were exploratory and not adjusted for multiple comparisons. IM HealthScience funded the trial and several authors had company roles. This combination cannot isolate peppermint’s contribution or establish general dyspepsia benefit from oil alone. Chey 2019 FDREST
This distinction also matters clinically: indigestion, reflux and IBS are different symptom patterns. Peppermint can aggravate reflux even when it is being considered for lower-bowel cramps. NCCIH IBS guidance
Gut healing, SIBO eradication and long-term prevention Insufficient
The evidence assessed here does not establish these outcomes. A short symptom trial cannot show prevention of future disease or sustained benefit after discontinuation. This is an evidence boundary, not proof that every untested effect is impossible. Long-term effectiveness remains uncertain in public clinical guidance. NCCIH IBS evidence
What works and what does not
| Claim | Verdict | Notes |
|---|---|---|
| A short-term IBS treatment option for selected adults | Possible benefit, uncertain independent magnitude | Consistent enough for a conditional guideline suggestion; conflicting modern trials and funding gaps remain |
| A proven benefit from any peppermint product | Unsupported | Preparation, population and endpoint differ |
| A reliably effective pediatric treatment | Not established | Recent controlled results were null |
| A reflux remedy | Poor fit | Can worsen heartburn |
| Peppermint tea equals an enteric-coated capsule | Unsupported equivalence | No matching exposure or delivery evidence |
| A microbiome reset or gut-lining repair | Not established | Appropriate clinical outcomes are missing |
Risks and reported side effects
| Aspect | Finding | Source |
|---|---|---|
| Reflux and irritation | Heartburn, indigestion and anal irritation can occur | NHS safety |
| Aggregate trial adverse events | Any adverse event RR 1.57 (95% CI 1.04–2.37) and reflux RR 1.67 (1.18–2.38) in the 2022 pooled trials | Ingrosso 2022 |
| Allergy | Peppermint or another capsule ingredient may provoke a reaction | NHS safety |
| Product-specific allergens | The examined UK Colpermin label lists peanut oil and cautions people with peanut or soya allergy | Colpermin label |
| Liver and biliary conditions | EMA's digestive-use summary excludes liver disease, gallstones, other bile-related problems and achlorhydria | EMA public summary |
| Pregnancy and breastfeeding | Data are limited; guidance differs in caution between products and institutions | NHS pregnancy page; product label |
A 2025 case letter described liver-enzyme elevations during escalating use of two peppermint-containing products, improving after withdrawal. Its original report contains inconsistent dose descriptions and additional care alongside withdrawal. A single case cannot establish incidence, a safe dose ceiling or which ingredient caused the abnormalities. The authors reported no manuscript-preparation support or conflicts; an NIH grant is separately indexed, and detailed individual disclosures and supply terms remain unresolved. Ali 2025 original case, reported financial declarations, indexed NIH grant
Safety note: Breathing difficulty, sudden swelling of the mouth or throat, or collapse requires emergency care. Do not experiment with concentrated oil in response to persistent or unexplained abdominal symptoms. New bowel bleeding, persistent vomiting, weight loss or worsening symptoms needs medical assessment. This is a selection of relevant risks, not a complete adverse-event inventory. NHS emergency allergy guidance, NHS suitability guidance
Interactions and important gaps
| Substance or condition | Mechanism or concern | Severity/status | Source |
|---|---|---|---|
| Antacids, PPIs and H2 blockers | Altered gastric conditions can interfere with intended release | Formulation-specific caution; check the actual product and pharmacist's advice | NHS interaction guidance |
| Felodipine | A 12-person experiment using 600 mg oil increased average drug exposure to 140% of the water condition, with wide individual variation | Human pharmacokinetic signal; clinical consequences and usual-capsule relevance uncertain | Dresser 2002 |
| Cyclosporine | Increased exposure in a rat experiment | Preclinical warning, not a verified human interaction magnitude; specialist review is appropriate | Wacher 2002 |
| Other medicines and herbal products | Laboratory metabolic effects do not establish every proposed clinical interaction | Comprehensive testing is absent | NHS evidence gap |
| Alcohol | May worsen dizziness or other adverse effects | Tolerability caution | NHS common questions |
| Existing reflux or hiatus hernia | Symptoms may worsen | A clinically relevant suitability issue | NCCIH IBS guidance |
NHS advice describes a two-hour gap from indigestion medicines. This does not prove that spacing neutralizes every effect of a long-acting acid suppressant or suits every release system. Check the full medicine list and particular capsule with a clinician or pharmacist; do not stop prescribed treatment to accommodate a supplement. NHS medicine guidance, Colpermin instructions
Who should avoid self-treatment
People with unexplained or alarm symptoms should first have the cause assessed. Reflux, gallbladder or liver disease, low stomach acid, pregnancy, breastfeeding and relevant allergies warrant individual review. The EMA and individual labels have different age limits; a research protocol is not permission to dose a child. EMA digestive-use restrictions, NHS suitability
An existing IBS care plan should not be abandoned because evidence certainty or financial independence is limited. These judgments describe what the reviewed studies establish, rather than whether a particular person should discontinue prescribed care. Treatment choices should be discussed with the treating clinician. ACG conditional recommendation, NCCIH guidance
Dosage and how it was taken in research
These are study exposures, not dosing recommendations. Different coatings and units are not interchangeable.
| Use case | Studied exposure | Duration | Notes |
|---|---|---|---|
| Adult IBS, US trial | 180 mg three times daily | 6 weeks | No superiority over placebo; Nee |
| Adult IBS, Dutch trial | 182 mg three times daily, two release designs; first-week titration | 8 weeks | Primary endpoints null; Weerts |
| Non-constipated adult IBS | 180 mg three times daily in a proprietary microsphere system | 4 weeks | Maker-funded study; Cash |
| Pediatric IBS/functional pain | Age-dependent capsule or sweet protocol with potential escalation | 8 weeks | No proven advantage; not reproduced as home instructions; Vermeijden |
| Drug-interaction experiment | 600 mg oil with felodipine | Acute crossover | Not a therapeutic digestive regimen; Dresser |
Gastro-resistant capsules should be used according to their actual instructions rather than crushed or chewed. Oil released early can irritate the upper digestive tract. Colpermin handling instructions
Animal and in vitro evidence excluded from benefit conclusions
The cyclosporine experiment was conducted in rats and included AvMax-affiliated authors. It explains a repeated interaction concern without establishing a human exposure or harm rate. The human felodipine abstract also reports microsomal experiments and a tentative intestinal-metabolism explanation. Laboratory enzyme effects cannot establish a clinically important interaction with every medicine using that pathway; the full interaction-paper methods and financial disclosures remain unavailable. Rat cyclosporine study, Human felodipine study
No animal, cell-culture or isolated-tissue result establishes the IBS benefit grade in this article. Mechanistic plausibility and efficacy are assessed separately.
Funding and financial relationships
Research funding at a glance
28 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
What the research money shows
The US programme has identifiable NIH cash financing and unresolved product-procurement terms. PERSUADE documents Will Pharma in-kind support and relevant author/employer agreements. Cash’s trial documents company financing and company-linked authors. The pediatric paper identifies company-provided products without specifying payment terms, alongside separately disclosed author relationships. These different relationships require source-specific interpretation; a public or charitable funder does not remove a commercial product or licensing stake. US protocol, PERSUADE disclosures, Cash disclosures, Pediatric disclosures
An arm's-length product purchase is not sponsorship. An undisclosed procurement arrangement remains unknown. Academic control over analysis is reassuring, but it does not erase manufacturer financing, donated products, commercial authorship or a relevant licensing stake. The same eligibility rule applies to favorable and unfavorable outcomes.
Companies, countries and backers
IM HealthScience was the US sponsor of Cash’s trial. Nestlé Health Science announced an agreement to acquire its business and brands in August 2020; Nestlé’s later report confirms closing in September 2020. IBgard is currently listed on the Nestlé Health Science website, whose corporate announcement identifies its global headquarters in Vevey, Switzerland. These later ownership records do not imply Nestlé financed the earlier trial. August agreement and company identity, September closing report, current IBgard page
Nestlé's 2025 governance report lists notified stakes of 5.04% for BlackRock, 5.547% for UBS Fund Management (Switzerland), and 3.006% for Capital Group. Those figures refer to notifications dated January 2022, May 2024 and January 2025 respectively, not a live October 2026 shareholder register. Investment-manager holdings do not establish control over a particular study. Ultimate fund clients and trial-level decision rights were not traced. Capital Group identifies its corporate headquarters in downtown Los Angeles, USA. 2025 report, significant shareholders; Capital Group headquarters disclosure
Will Pharma describes itself as a continuing family business with Dutch origins and Belgian operations. Its exact ultimate ownership percentages were not verified from primary filings. The business relationship to the Dutch trial is nevertheless explicit in the paper. Plant origin, oil-production country, capsule manufacturing country and a sponsor's headquarters should not be conflated. Will Pharma history
Documented money map

Plain-text version:
- NIH/NCCIH in the USA funded the US research program; product procurement remains unresolved
- ZonMw in the Netherlands funded PERSUADE, while Will Pharma provided in-kind capsules and held relevant commercial agreements
- US-based IM HealthScience funded the Cash trial and supplied company-linked authors
- Nestlé confirms the IM HealthScience acquisition closed in September 2020; this does not retrospectively attribute the earlier trial to Nestlé. Closing report
- Nestlé's report lists the dated BlackRock, UBS and Capital Group notifications above; these are corporate investments, not documented trial instructions
The trial literature spans several countries, while key product relationships in the modern studies are concentrated in US and Dutch/Belgian businesses. Nationality alone establishes neither reliability nor bias. Missing budgets, older trial disclosures and manufacturing details remain gaps. Funding is not proof of a false finding; it is relevant to the independence of corroboration.
Regulatory status
United Kingdom and European Union
The examined UK Colpermin product has a marketing authorization for IBS symptom relief. EMA’s assessment concerns specified peppermint-oil preparations; national authorities assess individual medicinal-product applications. This does not authorize every essential-oil bottle or provide an independent pooled treatment estimate. The March 2026 scientific-data call had a 15 March–15 June submission window, now marked closed; it is a review step rather than a new approval. UK label, EMA document record, original 2026 call
United States
A dietary supplement is not preapproved by FDA for safety and effectiveness in the way a drug is. Disease-treatment claims and general supplement marketing operate under different rules. A study, a trademark or an ingredient label should not be represented as FDA approval to treat IBS. FDA supplement questions
Frequently asked questions
Does peppermint oil work for IBS?
The 2022 adult pool suggested short-term relief with very low certainty, while the low-bias global and pain subsets differed. The 2021 guideline made a conditional suggestion, and modern adult primary-endpoint results were null. Known commercial ties and unresolved supply terms prevent a fully verified independent-only estimate or a dependable prediction for every product or person. Review, guideline, US trial, Dutch trial
Can I use peppermint tea instead?
Tea has a different composition and exposure. A preference for tea is not evidence that it reproduces a studied capsule's effect.
Why can something used for cramps worsen heartburn?
The intended lower-bowel effect does not make the same preparation suitable for the oesophagus or stomach. Reflux is a recognized adverse effect, including with some coated products.
Is the children's research positive?
The recent large Dutch comparison did not establish superiority. Its results and age-specific research protocols do not justify self-dosing children.
Does uncertain evidence mean my improvement is imaginary?
An individual’s improvement can be real while its cause remains uncertain. The review’s evidence and financial classifications describe study-level support, not a diagnosis of that person’s experience. Fluctuating symptoms, background care and the control-group comparison matter; financial uncertainty does not prove a study false. Placebo-programme protocol, controlled trial
Sources and funding notes
The tiers describe documented interests: 1 indicates no identified relevant stake in the available disclosures, 2 indirect ties, 3 an interested party, 4 direct commercial origin or support, and U unresolved financial provenance. These are provisional editorial classifications, not proof that every financial chain is known. Credibility A–D addresses the source’s role and accountability separately from study methods and formal GRADE certainty. Official guidance and corporate filings can document rules or ownership without proving the cited clinical trials independent.
| Source | Funding, ownership and country | Tier / credibility | Accuracy incentive and residual gap |
|---|---|---|---|
| Ingrosso 2022 review, accepted original | Accepted main paper recovered; no separate funding or COI declaration found in that version; final-publisher declarations and underlying finances unresolved | U / B provisional | Methods and full trial tables read; commercial underlying trials, very-low certainty and publication-bias concern |
| Nee 2021 | US academic trial; NIH award verified; complete main paper, final disclosures and procurement unresolved | U / B provisional | Structured abstract and public grant record read; no complete methods or financial clearance |
| Ballou 2017 protocol | NIH/NCCIH grants, USA; no competing interests declared; commercial product sources named without payment terms | U / B provisional | Prospective methods; not a completed result or procurement invoice |
| NIH award | US federal research agency | 1 / A for grant record | Public accountability; cash award alone cannot exclude in-kind support |
| Weerts 2020 | Netherlands; ZonMw, Will Pharma in-kind products and relevant licensing agreements | 4 / C | Detailed original outcomes and disclosures; null primaries and selected exploratory secondaries; known commercial ties |
| Cash 2016 | IM HealthScience, USA, funded study; consultant and company officers authored it | 4 / C | Controlled experiment; direct commercial stake |
| Vermeijden 2026 | Netherlands; SPIN supported by Cultuurfonds; Will Pharma/Fortuin procurement terms unknown; prior Will Pharma co-funding for Keszthelyi and Benninga company consultancies disclosed separately | U / B provisional; indirect author ties | Original abstract and indexed support/COI read; complete main tables and product payment terms unavailable; no pediatric superiority |
| Chey 2019 | IM HealthScience financing and company roles, USA | 4 / C | Trial methods; combination cannot isolate peppermint |
| Ali 2025 case report, disclosures, PubMed record | US academic clinicians; no manuscript-preparation support or conflicts declared; NIDDK R01 DK123549 separately indexed; detailed forms and supply terms unresolved | U / B provisional | Full main case letter read; individual disclosure forms unrecovered; single case, multiple products and dose inconsistencies limit attribution |
| Dresser 2002 | Canadian university and US AvMax affiliations; complete funding, author disclosures and company ownership unresolved | Commercial affiliations / C provisional | Original abstract and affiliations read; 12-person pharmacokinetic signal; human mechanism tentative; full paper unavailable |
| Wacher 2002 | US AvMax affiliations; complete funding, author disclosures and company ownership unresolved | Commercial affiliations / C provisional | Original rat abstract read; vehicle matters; no verified human magnitude or full-main financial clearance |
| ACG 2021 guideline | US professional society; no financial support reported; Chey discloses IM Health consulting and Moshiree Nestlé consulting | 3 / C | Original recommendation, methods and disclosures read; conditional low-quality advice; no independent-only trial pool |
| NCCIH peppermint overview | US federal NIH center, public research mission | 1 / A for public guidance | Named literature and accountability; summary is not a new trial |
| NCCIH IBS guidance | Same US public institution | 1 / A for guidance | Explains limits; does not certify underlying trial independence |
| NHS common questions | UK publicly funded health service | 1 / A for practical guidance | Public safety mandate; broad advice rather than a formulation trial |
| NHS side effects | UK public health service | 1 / A | Safety accountability; cannot supply precise incidence for every product |
| NHS suitability | UK public health service | 1 / A | Triage and medicine-use guidance; individual assessment still needed |
| NHS pregnancy and breastfeeding | UK public health service | 1 / A | Public guidance; acknowledges limited data |
| NHS interactions | UK public health service | 1 / A | Explicit knowledge gaps; timing advice is not a universal compatibility study |
| Colpermin SmPC | McNeil Products Limited, UK authorization holder; company-origin document hosted by emc; ultimate ownership unresolved | 4 / C | Regulated label accountability; used for contents, instructions and warnings, not independent efficacy |
| EMA public summary | EU agency headquartered in Netherlands; public contributions and regulated-industry fees | 2 / A for regulatory scope | Legal mandate; assessment includes literature with commercial ties |
| EMA assessment record | Same EU agency | 2 / A for document status | Dated adopted documents distinguished from consultation |
| EMA budget program | EU/EFTA contribution and service-fee revenue in the 2026 budget forecast | 2 / A for institutional finance | Official forecast tables read; not final receipts or evidence that a particular decision was purchased |
| FDA supplement guidance | USA; official federal regulatory guidance; agency-wide budget and funding mix not established by this cited page | Official role / A for legal scope; financing unverified | Current statutory Q&A read; used for supplement rules, not clinical efficacy or financial clearance |
| Nestlé acquisition agreement, complete announcement, closing report | Swiss corporate group, interested primary disclosure | 4 / C | Primary agreement, headquarters statement and September 2020 closing verified; promotional outcome claims excluded |
| IBgard corporate page | Nestlé Health Science, Switzerland; product sales | 4 / D for marketing, C for identity | Commercial incentive; used to establish brand connection and stated claims |
| Nestlé 2025 governance report | Listed Swiss company; disclosed institutional investors | 4 / C | Filing accountability; dated notifications, not real-time ownership |
| Will Pharma history | Dutch/Belgian family-business self-description; exact stakes unverified | 4 / C | Public corporate identity; promotional account is not an ownership audit |
Scope: selected digestive outcomes and safety sources. Full relevant originals were recovered for several trials and the adult synthesis, while some final papers, individual disclosure forms and supply terms remain unavailable. No complete independent-only trial census, product catalogue or interaction inventory is claimed.
Last reviewed: 1 October 2026.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
